Here's the latest company planning for gene-edited babies

The Next Frontier: The Race to Create Gene-Edited Babies. Imagine a world where future generations could be born free from inherited diseases, possibly even enhanced with traits like resistance to heart disease or Alzheimer's. This tantalizing vision is fueling a new wave of biotech entrepreneurs who believe the time has come to rigorously test—and perhaps one day realize—the dream of gene-edited babies. A bold new company is stepping into this controversial arena, having secured a staggering $30 million to form a public-benefit corporation focused on researching the safety and ethics of editing the DNA of human embryos. Their mission is not to rush into creating so-called designer babies, but to methodically investigate whether it's possible to correct harmful genes, or even install beneficial ones, before a child is born. The hope is to prevent illnesses at their origin, with changes that could be passed down through generations. This is not science fiction, but it's also not mainstream science—at least not yet. The idea of editing human embryos remains fraught with ethical, legal, and scientific concerns. In fact, when the first gene-edited babies were born in China just a few years ago, the scientist responsible ended up in prison. Many countries, including the United States, still ban the practice outright. Detractors warn of unknown consequences and argue that energy should focus on gene therapies for existing patients rather than rewriting the genetic destiny of future generations. Despite the opposition, the momentum is real. Several startups are now forming with the aim of developing technologies to safely create gene-edited babies, though they remain on the fringes of scientific credibility. Their founders argue that as gene-editing tools become more precise, society must confront the possibility of using them to enhance the human species itself. Some envision a not-so-distant future where editing an embryo's DNA could be as routine—and as affordable—as IVF is today. The broader tech and investment community is taking notice. High-profile figures in the cryptocurrency world and venture capitalists are openly supporting these efforts, seeing them as not just a business opportunity, but a potential societal obligation. There is a sense that if these technologies can be proven safe, resisting their adoption may be impossible. Still, mainstream scientists remain skeptical, if not openly hostile. Many leading figures in gene editing see these ventures as distractions at best and dangerous experiments at worst, warning that premature attempts could do more harm than good. Some have called for an immediate halt to efforts aimed at heritable genome editing, fearing unintended consequences that could ripple through generations. Yet, the founders of these new ventures remain undeterred. Their public stance is one of caution and responsibility, insisting that if their research shows gene editing isn't safe, that knowledge alone would be a valuable contribution. They argue that open discussion and rigorous study are needed to break the silence surrounding this topic, and to encourage more scientists to weigh in—publicly—on the future of human genetic engineering. As the debate intensifies, the stakes couldn't be higher. The outcome of this research could reshape not only medicine, but the very nature of what it means to be human.